BIAF · bioAffinity Technologies, Inc.
$0.40
+0.02 (+4.99%)
At close · Aug 14
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's current expected level of operating expenditures and the cash and cash equivalents on hand at June 30, 2026, management concludes that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 7, 2026
Market Cap
$3.26M
Shares
8.10M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $434,983 |
| J. Michael Edwards | Chief Financial Officer | $368,455 |
| Michael Edwards | CFO | $368,455 |
| Steven Girgenti | Executive Chairman | $261,860 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $477,155 |
| Steven Girgenti | Executive Chairman | $366,679 |
| J. Michael Edwards | Chief Financial Officer | $273,213 |
| Michael Edwards | CFO | $273,213 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $424,168 |
| Michael Dougherty | Vice President and CFO | $338,919 |
| Steven Girgenti | Executive Chairman | $248,745 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $351,287 |
| Vivienne Rebel | EVP; Chief Science & Medical Officer | $257,566 |
| Steven Girgenti | Executive Chairman | $153,333 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $264,404 |
| Vivienne Rebel | EVP; Chief Science & Medical Officer | $249,790 |
| Steven Girgenti | Executive Chairman | $193,222 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Gary Rubin | Board | Resigned | 2025-08-18 |
| John J. Oppenheimer | member of the Board | Appointed | 2025-08-18 |
| Roberto Rios | member of the Board | Appointed | 2025-08-18 |
| J. Michael Edwards | Chief Financial Officer | Appointed | 2024-10-10 |
| Michael Edwards | Interim Chief Financial Officer and Principal Accounting Officer | Appointed | 2024-08-23 |
| Michael Dougherty | Chief Financial Officer and Principal Accounting Officer | Resigned | 2024-08-23 |
| Roby Joyce, MD | Director | Appointed | 2024-06-05 |
| Jamie Platt, PhD | Director | Appointed | 2024-06-05 |
| Stuart Diamond | Director | Appointed | 2024-06-05 |
| Gary Rubin | Director | Appointed | 2024-06-05 |
| Peter Knight | Director | Appointed | 2024-06-05 |
| Steven Girgenti | Director | Appointed | 2024-06-05 |
| Robert Anderson | Director | Appointed | 2024-06-05 |
| Maria Zannes | Director | Appointed | 2024-06-05 |
| Mohsin Y. Meghji | Board of Directors | Resigned | 2023-12-05 |
| Jamie Platt, Ph.D. | director | Appointed | 2023-12-05 |
| Roby Joyce, M.D. | Laboratory Director and Medical Director of Precision Pathology Laboratory Services, LLC | Appointed | 2023-09-20 |
| Xavier Reveles | Chief Operating Officer | Appointed | 2023-09-20 |
| Roby P. Joyce | Board of Directors | Appointed | 2023-09-20 |
| Mohsin Meghji | director | Appointed | 2023-06-07 |
| Gary Rubin | director | Appointed | 2023-06-07 |
| Robert Anderson | director | Appointed | 2023-06-07 |
| Stuart Diamond | director | Appointed | 2023-06-07 |
| Peter Knight | director | Appointed | 2023-06-07 |
| Steven Girgenti | director | Appointed | 2023-06-07 |
Key facts
CIK
1712762
CUSIP
09076W307
13F (30d)
21 filings
21 filers
Visit website
Investor relations